Low dose enzalutamide in the Martinique

Published: 12 July 2026| Version 3 | DOI: 10.17632/257psct2ds.3
Contributor:

Description

Data and script supporting the analyses of the manuscript: Non-inferior survival and enhanced longevity with low-dose enzalutamide in prostate cancer. The study has no funding. Authors will respond to queries to the best of their availability. Data freeze as of May 2, 2025. Version 2: Script enza_covid_03_public.R same as Version 1. Data file enzadata17_public.xlsx : same data as Version 2, edited to remove non-relevant external links and old unused sheets. Version 3: Manuscript revision. Update with script: enza_covid_03_public_rev-jpm.R Version 4 updates, completed with prescribers list. enza_covid_03_public_rev-jpm.R enzadata17_public-prescriber.xlsx

Files

Steps to reproduce

R script should run as-is in the same folder as the Excel dataset.

Institutions

Categories

Prostate Cancer, Toxicity, Androgen Inhibitor, Dose Response, Drug Dose

Licence